What is the modified World Health Organization (WHO) maternal cardiovascular risk classification for a pregnant woman with chronic diastolic heart failure, ejection fraction 45–50 %, grade 3 diastolic dysfunction, and non‑ischemic cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Modified WHO Classification for This Patient

This patient with chronic diastolic heart failure, ejection fraction 45-50%, grade 3 diastolic dysfunction, and non-ischemic cardiomyopathy falls into WHO Class II-III (depending on individual clinical status), representing significantly increased risk of maternal mortality or severe morbidity that requires expert counseling and intensive monitoring. 1

Risk Classification Rationale

The modified WHO classification specifically categorizes "mild left ventricular impairment" as WHO II-III (depending on individual factors). 1 While this patient's LVEF of 45-50% is technically preserved, the presence of grade 3 diastolic dysfunction represents significant cardiac impairment that elevates risk beyond simple LVEF considerations. 1

Key Distinguishing Features from WHO IV

This patient does not meet WHO Class IV criteria because: 1

  • LVEF is not <30% (the threshold for severe systemic ventricular dysfunction)
  • No documentation of NYHA Class III-IV symptoms
  • No pulmonary arterial hypertension mentioned
  • Not peripartum cardiomyopathy with residual impairment

Factors Determining II vs III Classification

The final placement between WHO II and III depends on: 1, 2

  • Current NYHA functional class (Class II would favor WHO II; Class III would mandate WHO III)
  • Presence of heart failure symptoms at baseline
  • Severity of diastolic dysfunction (grade 3 is severe and concerning)
  • Associated valvular disease or other comorbidities
  • Response to medical therapy and clinical stability

Clinical Management Algorithm

If Classified as WHO Class II (5.7-10.5% maternal risk):

  • Cardiology and obstetric follow-up every trimester 2
  • Multidisciplinary team assessment at specialist center 1, 2
  • Monthly monitoring may be needed if symptoms develop 2

If Classified as WHO Class III (19-27% maternal risk):

  • Monthly or bimonthly cardiology and obstetric review throughout pregnancy 1, 2
  • Mandatory management by expert multidisciplinary pregnancy heart team 2
  • Hospital delivery at specialized center with advanced cardiac support 1
  • Continuous hemodynamic monitoring during labor and delivery 1

Critical Prognostic Considerations

Cardiac events occur in 32-60% of patients with left ventricular dysfunction during pregnancy or early postpartum. 3 The CARPREG risk score may provide additional prognostic information, with LVEF <40% being a major predictor of adverse outcomes. 3, 4

High-Risk Features to Monitor:

  • Development of NYHA Class III-IV symptoms (would reclassify to very high risk) 3
  • Atrial fibrillation or ventricular arrhythmias 3
  • Worsening mitral regurgitation secondary to diastolic dysfunction 3
  • Pre-eclampsia (strongly associated with heart failure, OR 7.1) 5

Timing of Complications

Heart failure typically develops at median 31 weeks gestation, with highest incidence at end of second trimester (34%) or peripartum period (31%). 5 This patient requires intensified surveillance during these critical windows given the severe diastolic dysfunction. 5

Essential Pitfall to Avoid

Do not rely solely on preserved LVEF to underestimate risk. 1, 3 Grade 3 diastolic dysfunction represents severe cardiac impairment that significantly limits the heart's ability to accommodate the 30-50% increase in cardiac output required during normal pregnancy. 6 The modified WHO classification's strength is that it integrates all cardiovascular risk factors beyond simple LVEF measurements. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Maternal Cardiovascular Risk Classification and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Contraindications for Nitrous Oxide Inhalation in Pregnant Women with Low Ejection Fraction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is there a risk score to predict adverse outcomes in pregnant women with dilated cardiomyopathy (DCM) and severely reduced left ventricular function (LVF)?
What is the appropriate management for a 30‑week pregnant woman with newly diagnosed systolic heart failure (ejection fraction ~30%) presenting with dyspnea and NYHA class II?
What are the management and treatment options for a pregnant woman with pre-existing left-sided heart failure?
Is pregnancy contraindicated in a woman with dilated cardiomyopathy and severely reduced left ventricular (LV) function, specifically an ejection fraction (EF) of 35%?
What is the role of the Carpreg (Cardiac Disease in Pregnancy) score in assessing cardiac risk in a pregnant woman with a history of cardiac disease?
How should primary adrenal insufficiency be diagnosed and managed?
In a patient with a Do‑Not‑Resuscitate (DNR) order who has an implanted pacemaker or implantable cardioverter‑defibrillator (ICD), how should the device be managed—continue pacing, adjust settings, or deactivate?
How should a 37‑year‑old woman with normal cervical cytology and a positive high‑risk HPV test (non‑16/18) be managed?
What is the recommended acyclovir dosing for varicella (chickenpox) in healthy children, immunocompetent adolescents/adults, and immunocompromised patients?
How should I treat a 55‑year‑old patient with trigeminal neuralgia affecting the V2/V3 distribution, presenting with brief electric‑shock‑like facial pain triggered by light touch, chewing, or speaking?
What is the recommended initial intravenous furosemide dose and titration plan for an adult with acute pulmonary edema, and how should it be adjusted for elderly patients or those with chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.